8-K: GeoVax Provides Nasdaq Listing Update, Reaffirms Strategy

GeoVax Labs, Inc. updates on its Nasdaq listing appeal hearing scheduled for October 13, 2026, while reaffirming its commitment to advancing its GEO-MVA vaccine and Gedeptin oncology programs.

Summary

• GeoVax Labs, Inc. has provided an update regarding its Nasdaq listing status, confirming that a hearing before the Nasdaq Hearings Panel is scheduled for October 13, 2026, to appeal a delisting determination based on the minimum bid price requirement.
• The company's request for a hearing has stayed any delisting actions, and its common stock is expected to continue trading on The Nasdaq Capital Market under the symbol GOVX at least through the hearing and any subsequent extension period.
• GeoVax intends to present a plan to regain and maintain compliance with Nasdaq listing standards at the hearing.
• The company is reaffirming its strategic priorities, including advancing its GEO-MVA vaccine program towards a pivotal Phase 3 clinical trial, strengthening manufacturing and global preparedness capabilities, and engaging potential partners.
• In oncology, GeoVax is advancing Gedeptin, a gene-directed enzyme prodrug therapy, into combination strategies.
• The company also maintains a broader MVA-based vaccine platform for high-consequence infectious diseases.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive development, as the company is actively addressing a critical listing requirement and reaffirming its strategic focus, though the outcome of the hearing remains uncertain.

Positives

• The company has successfully requested a hearing before the Nasdaq Hearings Panel, which has stayed any delisting actions.
• GeoVax's common stock is expected to continue trading on The Nasdaq Capital Market at least through the hearing period.
• The company has a plan to present to regain and maintain Nasdaq listing compliance.
• Strategic priorities, including the GEO-MVA vaccine program and Gedeptin oncology therapy, remain the focus.
• Growing emphasis on vaccine supply resilience and biodefense preparedness provides a favorable backdrop for GeoVax's programs.

Negatives

• The company received a delisting determination on August 27, 2026, relating to the minimum bid price requirement.
• The outcome of the Nasdaq Hearings Panel is uncertain, and continued listing is not guaranteed.
• The company faces near-term corporate and financing priorities that need to be addressed.

Risks

• Failure to regain and maintain compliance with Nasdaq listing standards could result in delisting.
• The company's ability to obtain acceptable results from ongoing or future clinical trials.
• Challenges in developing and manufacturing products in a timely manner with desired characteristics.
• Ensuring the safety and efficacy of investigational products for human use.
• Obtaining necessary regulatory approvals for licensing and marketing.
• The need to raise required capital to continue and complete development.
• Development of competitive products that may be more effective or easier to use.
• Securing favorable manufacturing and distribution agreements.

Future Outlook

The company plans to initiate a pivotal Phase 3 clinical trial for GEO-MVA in the second half of 2026. Gedeptin is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax continues to pursue manufacturing and product innovations, evaluate strategic partnerships, and address corporate and financing priorities.

Management Comments

• "We remain committed to maintaining GeoVaxs Nasdaq listing and look forward to presenting our compliance plan to the Hearings Panel."
• "Importantly, the Nasdaq process does not change our strategic priorities or our focus on execution."
• "We continue to advance GEO-MVA toward its planned pivotal Phase 3 clinical program, pursue opportunities to strengthen our manufacturing and global preparedness capabilities, and engage potential strategic, funding and development partners across our portfolio."
• "Our focus remains on building long-term value from GeoVaxs vaccine and immuno-oncology programs while addressing the Companys near-term corporate and financing priorities."
• "We believe the progress across our programs, together with the growing emphasis on vaccine supply resilience, biodefense preparedness and expanded global access, provides a strong foundation for our continued efforts."

Industry Context

StockSavvy.ai notes that the biotechnology sector, particularly companies focused on infectious diseases and oncology, often faces scrutiny regarding listing requirements due to the long development timelines and capital-intensive nature of research. The increased global focus on biodefense and vaccine supply resilience may provide a more favorable environment for companies like GeoVax.

Stakeholder Impact

• Shareholders: Continued trading on Nasdaq is positive, but the risk of delisting remains a concern. Progress on development programs could drive future value.
• Employees: Maintaining Nasdaq listing provides stability and supports ongoing operations and recruitment.
• Partners and Creditors: Continued listing and progress on development programs are important for maintaining confidence and potential collaborations or financing.

Next Steps

• Present a plan to regain and maintain compliance with Nasdaq listing standards at the hearing on October 13, 2026.
• Initiate a pivotal Phase 3 clinical trial for GEO-MVA in the second half of 2026.
• Advance Gedeptin into combination strategies, including planned neoadjuvant and first-line settings.
• Pursue opportunities to strengthen manufacturing and global preparedness capabilities.
• Engage potential strategic, funding, and development partners.

Key Dates

Recommendation

The company is actively addressing a critical Nasdaq listing issue and has a plan to present, which is a positive step. However, the outcome of the hearing is uncertain, and the company still faces significant development and financing risks. While strategic priorities are being advanced, the immediate focus on listing compliance and near-term financing needs warrants a cautious 'hold' recommendation until the listing status is resolved and further clarity on financing is provided.

Keywords

Nasdaq Listing, Biotechnology, Vaccine Development, Immunotherapies, Clinical Trials, Biodefense, Oncology, Mpox Vaccine